"10.1371_journal.pone.0009430","plos one","2010-03-04T00:00:00Z","Martine Humbert; Nathalie Castéran; Sébastien Letard; Katia Hanssens; Juan Iovanna; Pascal Finetti; François Bertucci; Thomas Bader; Colin D Mansfield; Alain Moussy; Olivier Hermine; Patrice Dubreuil","AB Science SA, Paris, France; Inserm U891, Centre de Recherche en Cancérologie de Marseille, Signalisation, Hématopoïèse et Mécanismes de l'Oncogenèse, Centre de Référence des Mastocytoses, Marseille, France; Institut Paoli-Calmettes, Marseille, France; Université de la Méditerranée, Marseille, France; Inserm U624, Stress Cellulaire, Parc Scientifique et Technologique de Luminy, Marseille, France; Inserm, U891, Centre de Recherche en Cancérologie de Marseille, Département d'Oncologie Moléculaire, Département d'Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France; Hôpital Necker, Service d'Hématologie, CNRS UMR 8147, Centre de Référence des Mastocytoses, Université Paris V René Descartes, Paris, France","Conceived and designed the experiments: MH JLI AM OH PD. Performed the experiments: MH NC SL KH PF FB PD. Analyzed the data: MH NC JLI PF FB TB CM PD. Contributed reagents/materials/analysis tools: MH JLI PD. Wrote the paper: MH NC FB TB CM AM OH PD.","Masitinib is under clinical development by the study sponsor, AB Science, S.A., Paris, France. AB Science is the proprietary holder of masitinib and A.M. is an applicant on numerous patents pertaining to masitinib. M.H. and A.M. are employees and shareholders of AB Science. P.D. and O.H. are consultants and shareholders of AB Science. N.C., K.H., T.B. and C.D.M. (medical writer) are employees of AB Science. No other conflicts of interest have been declared. The authors confirm that these interests do not alter their adherence to all the PLoS ONE policies on sharing data and materials.","2010","03","Martine Humbert","MH",12,TRUE,5,7,8,8,TRUE,TRUE,FALSE,0,NA,FALSE
